Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCH-IV for children and adolescents with Langerhans cell histiocytosis
NL-OMON59670Phase 3Active, not recruiting
- Sponsor
- St. Anna Children's Cancer Research Institute
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vinblastine, prednisone, cytarabine, vincristine, indomethacin and 3 more in Langerhans cell histiocytosis (LCH) (6 arms), sponsored by St. Anna Children's Cancer Research Institute. Primary endpoints: Reactivation-free survival, Overall survival and 4 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
vinblastineprednisonecytarabinevincristineindomethacin
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NL-OMON59670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59670.